NEW YORK, Aug 29 – Sequenom said Wednesday it had entered an agreement with GlaxoSmithKline to create a SNP assay portfolio that would cover the entire human genome.
"Our immediate goal is to establish a SNP assay portfolio covering all SNPs,” Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.
“We are confident that Sequenom can complete a project of this magnitude within our timelines and utilize their technology to enable rapid use of whole genome SNP mapping," he added.
Under the terms of the deal, GlaxoSmithKline of London will have access to Sequenom’s SNP assay portfolio. The pharmaceutical company then plans to select SNP candidates for genome-wide association studies.
San Diego-based Sequenom said the deal represented a “multimillion dollar agreement” but did not disclose exact terms.
The companies were not immediately available to discuss the announcement.